Pancreatitis - Pipeline Review, H1 2018

  • ID: 4479909
  • Report
  • 79 pages
  • Global Markets Direct
1 of 5
Pancreatitis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Pancreatitis - Pipeline Review, H1 2018, provides an overview of the Pancreatitis (Gastrointestinal) pipeline landscape.

Pancreatitis is an inflammation of pancreas. Symptoms include upper abdominal pain, nausea, vomiting, and tenderness when touching the abdomen, weight loss and upper abdominal pain. Risk factors include alcoholism, smoking, family history of pancreatitis, infection, injury to the abdomen and pancreatic cancer. Treatment includes antibiotics and medication to relieve pain.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Pancreatitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Pancreatitis (Gastrointestinal)
Table of Contents 2List of Tables The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatitis (Gastrointestinal) pipeline guide
Table of Contents 2List of Tables The guide covers therapeutics under Development by Companies /Universities /Institutes,
Table of Contents 2List of Tables

Pancreatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is
Table of Contents 2List of Tables Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Pancreatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pancreatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pancreatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatitis (Gastrointestinal)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pancreatitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pancreatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5
Introduction

Report Coverage

Pancreatitis - Overview

Pancreatitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Pancreatitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pancreatitis - Companies Involved in Therapeutics Development

Angion Biomedica Corp

Bharat Serums And Vaccines Ltd

CalciMedica Inc

Cypralis Ltd

DiaMedica Therapeutics Inc

Generon (Shanghai) Corp Ltd

GlaxoSmithKline Plc

LipimetiX Development Inc

MallInckrodt Plc

Novartis AG

Pharming Group NV

Sun BioPharma Inc

Takeda Pharmaceutical Co Ltd

Pancreatitis - Drug Profiles

AAD-2004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AEM-2802 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AEM-2814 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANG-3070 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C1 esterase inhibitor (recombinant) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBT-1430E - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBT-1440G - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-1233 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CM-128 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CM-4620 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DM-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

F-652 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-180 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2795039 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-3335065 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-428 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-6288B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-3964 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptides to Agonize renalase for Acute Pancreatitis, Acute Kidney Injury and Cisplatin Induced Kidney Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBP-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBP-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Cyclophilin for Gastrointestinal and Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit KMO for Pancreatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Soluble Epoxide Hydrolase for Acute Pancreatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Trypsin for Pancreatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-671 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ulinastatin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Withaferin A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pancreatitis - Dormant Projects

Pancreatitis - Discontinued Products

Pancreatitis - Product Development Milestones

Featured News & Press Releases

Nov 09, 2017: Cypralis to present pre-clinical data on novel cyclophilin D inhibitor CC-1233 for acute pancreatitis at the American Pancreatic Association meeting

Sep 18, 2017: Cypralis granted new Innovate UK feasibility stage award to develop cyclophilin inhibitors targeting fibrotic diseases

Aug 10, 2017: Sun BioPharma Provides Clinical Update

May 24, 2017: CalciMedica Receives Fast-Track Designation for CM4620, a Novel CRAC Channel Inhibitor to Treat Acute Pancreatitis

Feb 01, 2017: The NIH Awards Sun BioPharma Grant to Study SBP-101 for the Treatment of Pancreatitis

Jan 05, 2017: CalciMedica Initiates Phase 1 Clinical Studies for CRAC Channel Inhibitor

Oct 24, 2016: Sun BioPharma to Present at the Innovation Biotech Showcase on October 26th

Appendix

Methodology

Coverage

Secondary Research

Secondary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Pancreatitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pancreatitis - Pipeline by Angion Biomedica Corp, H1 2018

Pancreatitis - Pipeline by Bharat Serums And Vaccines Ltd, H1 2018

Pancreatitis - Pipeline by CalciMedica Inc, H1 2018

Pancreatitis - Pipeline by Cypralis Ltd, H1 2018

Pancreatitis - Pipeline by DiaMedica Therapeutics Inc, H1 2018

Pancreatitis - Pipeline by Generon (Shanghai) Corp Ltd, H1 2018

Pancreatitis - Pipeline by GlaxoSmithKline Plc, H1 2018

Pancreatitis - Pipeline by LipimetiX Development Inc, H1 2018

Pancreatitis - Pipeline by MallInckrodt Plc, H1 2018

Pancreatitis - Pipeline by Novartis AG, H1 2018

Pancreatitis - Pipeline by Pharming Group NV, H1 2018

Pancreatitis - Pipeline by Sun BioPharma Inc, H1 2018

Pancreatitis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Pancreatitis - Dormant Projects, H1 2018

Pancreatitis - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Pancreatitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Pancreatitis - Companies Involved in Therapeutics Development
  • Angion Biomedica Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll